Skip to main content
NTRR
OTC Life Sciences

Neutra Life Sciences Forms Women's Health JV, Secures New Clinical Trials

Reported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$0
Mkt Cap
$583.58K
52W Low
$0
52W High
$0
52W Position
Off High info
67% below high
Rel. Volume
Market data snapshot near publication time

Summary

Neutra Corp's subsidiary, Neutra Life Sciences, announced a new joint venture with Women's Healthcare Center of Baytown, expanding its clinical research site network into women's health. The subsidiary also secured new clinical trials in Oncology, Dermatology, Pulmonology, and Women's Health, along with new sponsor contracts. For a micro-cap company, this expansion of partnerships and trial portfolio represents significant business development and potential for future revenue growth. The company anticipates continued growth and additional trial opportunities through the second half of 2026.

At the time of this announcement, NTRR was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $583.6K. The 52-week trading range was $0.00 to $0.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

NTRR - Latest Insights

NTRR
Jun 29, 2026, 3:29 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.0001
Real-time Price: $0.0001 info
Change: $0 (0%) info
Market Cap: $583.58K info